—Exhibition review —
The three-day 22nd World Pharmaceutical Ingredients China Exhibition (CPHI China 2024) successfully concluded on June 21, 2024 at the Shanghai New International Expo Center.
●Exhibition site
Jinran Biotech once again made its appearance at this world-famous industry event. At the exhibition, the booth of Jinran Biotechnology was crowded with people. Domestic and foreign customers stopped to watch, showing great interest and concern in the demonstrated chiral compound synthesis technology. Jinran Biotechnology uses its leading and unique synthetic biology technology to not only improve the quality and purity of its products, but also greatly reduce production costs and environmental pollution, and contribute to global green and sustainable development. In addition, Jinran Biotech's strict and complete quality system ensures the quality and safety of its products, winning the trust and praise of customers.
● Communication and negotiation
During the exhibition, Jinran Biotechnology also had in-depth exchanges and discussions with many customers in the fields of medicine, health products, cosmetics and other fields, and established extensive cooperative relationships. These customers spoke highly of Jinran Biotechnology's technical strength and product quality, and expressed that they would further strengthen cooperation with Jinran Biotechnology and jointly promote the development of related industries.
● Looking to the future
In short, Jinran Biotechnology's wonderful appearance at the exhibition not only demonstrated its leading and unique technology, but also conveyed its persistent pursuit of green, environmental protection and sustainable development. We have reason to believe that in the future development, Jinran Biotechnology will continue to make greater contributions to innovation and development in the field of biological synthesis technology.
— Company introduction—
Jinran Biotechnology was established in June 2020. It is a green and intelligent manufacturing enterprise of high-quality chiral compounds and materials integrating R&D, production and sales. The company relies on the founding team's more than ten years of R&D and industrialization experience in synthetic biology and is committed to the design, R&D, production and sales of new chiral molecules and materials.
Currently, the company has 4 major technology platforms and 7 product pipelines, and is committed to helping humans realize their desire to create a better life through biosynthesis!
Post time: Jun-27-2024